1. Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease 
Pantelis A. Sarafidis, MD, PhD, Suying Li, PhD, Shu-Cheng Chen, MS, Allan J. Collins, MD, Wendy W. Brown, MD, MPH, Michael J. Klag, MD, MPH, George L. Bakris, MD 
The American Journal of Medicine 
Volume 121, Issue 4, Pages (April 2008)
DOI: /j.amjmed
Copyright © 2008 Elsevier Inc. Terms and Conditions

2. Figure 1
Participant eligibility and recruitment. KEEP=Kidney Early Evaluation Program; eGFR=estimated glomerular filtration rate; ACR=albumin-to-creatinine ratio; BMI=body mass index.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2008 Elsevier Inc. Terms and Conditions

3. Figure 2
Prevalence, awareness, treatment, and control of hypertension to recommended systolic goal (<130 mm Hg) by chronic kidney disease stage. Note total cohort has an N=10,813. Prevalence is defined by systolic blood pressure≥130 mm Hg or diastolic blood pressure≥80 mm Hg or use of medication. All comparisons between stages for all categories at P<.0001.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2008 Elsevier Inc. Terms and Conditions

4. Figure 3
Prevalence, awareness, treatment, and control of hypertension in total cohort by chronic kidney disease stage with<140/90 mm Hg as a threshold. Note total cohort has an N=10,813. Prevalence of systolic blood pressure≥140 mm Hg or diastolic blood pressure≥90 mm Hg or use of medication. All comparisons between stages are significant to a P< BP=blood pressure.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2008 Elsevier Inc. Terms and Conditions